Ivabradin Genericon

Ivabradine Hydrochloride, the active ingredient in Ivabradin Genericon, is an If channel inhibitor presented as an oral tablet for systemic use. It is indicated for chronic stable angina pectoris and for heart failure with reduced ejection fraction in suitable patients and is approved for use in the European Union.

GNH USA supplies Ivabradin Genericon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to strict quality standards and provides regulatory documentation for global distribution.

Ivabradin Genericon, an If channel inhibitor, is used in cardiovascular conditions where heart‑rate reduction improves outcomes.

- Chronic stable angina pectoris: lowers heart rate to reduce frequency of angina attacks and improve exercise tolerance. - Heart failure with reduced ejection fraction: decreases heart rate, helping to alleviate symptoms and may reduce hospitalisations in patients with systolic dysfunction.

Ivabradin Genericon may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate below prescribed target. - Headache. - Dizziness or light‑headedness.

Serious or Rare Side Effects: - Symptomatic bradyarrhythmia requiring medical intervention. - Atrial fibrillation or other serious cardiac arrhythmias. - Severe hypotension or syncope. - Allergic reactions such as rash, angioedema, or anaphylaxis.

When prescribing Ivabradin Genericon, clinicians should observe several safety considerations.

- Baseline heart rate assessment: ensure resting heart rate is ≥70 bpm before initiation. - Contraindications: avoid in patients with severe hypotension, sick sinus syndrome, or acute decompensated heart failure. - Hepatic impairment: use with caution and consider dose adjustment in moderate to severe liver disease. - Concomitant rate‑lowering drugs: monitor for excessive bradycardia when combined with beta‑blockers or digoxin. - CYP3A4 inhibitors: avoid strong inhibitors that may increase plasma levels. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Ivabradin Genericon can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole): may markedly increase ivabradine exposure and cause severe bradycardia. - Co‑administration with other heart‑rate‑lowering agents (beta‑blockers, digoxin, verapamil): risk of excessive slowing of heart rate and symptomatic bradycardia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampicin, carbamazepine, phenytoin): may reduce ivabradine plasma concentrations, diminishing therapeutic effect. - Verapamil (moderate CYP3A4 inhibitor): can raise ivabradine levels; dose adjustment may be required. - Antihypertensive agents: additive blood pressure lowering; monitor blood pressure and adjust therapy as needed.